Your browser doesn't support javascript.
loading
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Quintela-Fandino, Miguel; Holgado, Esther; Manso, Luis; Morales, Serafin; Bermejo, Begoña; Colomer, Ramon; Apala, Juan V; Blanco, Raquel; Muñoz, Manuel; Caleiras, Eduardo; Iranzo, Vega; Martinez, Mario; Dominguez, Orlando; Hornedo, Javier; Gonzalez-Cortijo, Lucia; Cortes, Javier; Gasol Cudos, Ariadna; Malon, Diego; Lopez-Alonso, Antonio; Moreno-Ortíz, María C; Mouron, Silvana; Mañes, Santos.
Afiliação
  • Quintela-Fandino M; Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain. mquintela@cnio.es.
  • Holgado E; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. mquintela@cnio.es.
  • Manso L; Medical Oncology Department, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain. mquintela@cnio.es.
  • Morales S; Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
  • Bermejo B; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Colomer R; Medical Oncology Department, Hospital Universitari Arnau Vilanova, Lleida, Spain.
  • Apala JV; Medical Oncology Department, Hospital Clínico Universitario, Valencia, Spain.
  • Blanco R; INCLIVA, Valencia, Spain.
  • Muñoz M; CIBERONC, Instituto Carlos III, Madrid, Spain.
  • Caleiras E; Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.
  • Iranzo V; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Martinez M; Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
  • Dominguez O; Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.
  • Hornedo J; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.
  • Gonzalez-Cortijo L; Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Darwin, 3, 28049, Madrid, Spain.
  • Cortes J; Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029, Madrid, Spain.
  • Gasol Cudos A; Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center, Madrid, Spain.
  • Malon D; CIBERONC, Instituto Carlos III, Madrid, Spain.
  • Lopez-Alonso A; Medical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
  • Moreno-Ortíz MC; Medicine Department, Universitat de Valencia, Valencia, Spain.
  • Mouron S; Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Mañes S; Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center, Madrid, Spain.
Breast Cancer Res ; 22(1): 124, 2020 11 11.
Article em En | MEDLINE | ID: mdl-33176887
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Anticorpos Monoclonais Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Breast Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Espanha